naion and glp 1 GLP-1 medicine non-arteritic anterior ischemic optic neuropathy: Literature review and perspectives The popularity of GLP-1 agonists

(34) Experimental and clinical studies demonstrate that GLP-1RAs reduce the production of proinflammatory cytokines (e.g., TNF- , IL-6, Interleukin-1 - IL-1) and chemokines (e.g., Monocyte Chemoattractant Protein-1 - MCP-1, CXCL10), while increasing anti-inflammatory cytokines such as Interleukin-10 (IL-10)

Continuous use up to 3 to 6 months sometimes occurs under medical monitoring

Face and body use Suitable for multiple areas needing hydration and comfort

AstraZeneca executives have said the pill is rapidly absorbed and doesn't stay in the stomach long, which could reduce side effects relative to existing treatments

The article describes Retatrutide as a single peptide with agonist activity at GIP, GLP-1, and glucagon receptors and notes that the Phase 2 data informed later development planning